NeuroBo Pharmaceuticals, Inc. (NRBO)

NeuroBo Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	25	18	5	32	86	5
Market Cap Growth	3.95%	284.34%	-85.62%	-62.38%	1556.82%	-54.95%
Enterprise Value	11	-4	-29	16	76	-9
PE Ratio	-	-1.44	-0.33	-2.12	-2.91	-0.24
PB Ratio	2.65	1.08	0.22	2.22	11.97	0.42
P/FCF Ratio	-1.36	-1.65	-0.40	-2.14	-8.01	-0.72
P/OCF Ratio	-1.37	-1.66	-0.40	-2.14	-8.01	-0.74
EV/EBITDA Ratio	-0.26	0.34	2.44	-1.06	-2.58	0.40
EV/EBIT Ratio	-0.26	0.34	2.44	-1.06	-2.57	0.40
EV/FCF Ratio	-0.29	0.40	2.45	-1.07	-7.08	1.19
Debt / Equity Ratio	0.02	0.01	-	0.00	0.01	0.01
Debt / EBITDA Ratio	-0.01	-0.02	-	0.00	0.00	-0.01
Debt / FCF Ratio	-0.01	-0.02	-	0.00	-0.01	-0.02
Quick Ratio	2.34	3.76	2.83	7.60	2.73	6.69
Current Ratio	2.46	3.78	2.85	7.69	2.89	6.78
Interest Coverage	-	-	-5.37	-	-	-967.73
Return on Equity (ROE)	-90.20%	-59.40%	-115.30%	-141.00%	-322.70%	-482.30%
Return on Assets (ROA)	-69.50%	-45.40%	-86.40%	-122.90%	-231.60%	-319.40%
Return on Capital (ROIC)	-197.28%	-94.07%	-90.24%	-104.30%	-407.24%	-162.60%
Earnings Yield	-62.09%	-69.53%	-299.32%	-47.11%	-34.41%	-409.43%
FCF Yield	-55.22%	-60.49%	-250.82%	-46.66%	-12.49%	-139.34%
Buyback Yield / Dilution	-0.60%	-1476.33%	-233.62%	-42.72%	-210.43%	-22.88%
Total Shareholder Return	-0.60%	-1476.33%	-233.62%	-42.72%	-210.43%	-22.88%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).